BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, Brown RJ. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses 2015;7:3995-4046. [PMID: 26193307 DOI: 10.3390/v7072809] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Séron K, Sahuc M, Rouillé Y. Natural Products and Hepatitis C Virus. In: Mérillon J, Riviere C, editors. Natural Antimicrobial Agents. Cham: Springer International Publishing; 2018. pp. 289-327. [DOI: 10.1007/978-3-319-67045-4_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Grzyb K, Czarnota A, Brzozowska A, Cieślik A, Rąbalski Ł, Tyborowska J, Bieńkowska-Szewczyk K. Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex. Sci Rep 2016;6:30627. [PMID: 27481352 DOI: 10.1038/srep30627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
3 Uddin R, Downard KM. Subtyping of hepatitis C virus with high resolution mass spectrometry. Clinical Mass Spectrometry 2017;4-5:19-24. [DOI: 10.1016/j.clinms.2017.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ferns RB, Tarr AW, Hue S, Urbanowicz RA, McClure CP, Gilson R, Ball JK, Nastouli E, Garson JA, Pillay D. Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals. Virology 2016;492:213-24. [PMID: 26971243 DOI: 10.1016/j.virol.2016.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Falcón V, Acosta-Rivero N, González S, Dueñas-Carrera S, Martinez-Donato G, Menéndez I, Garateix R, Silva JA, Acosta E, Kourı J. Ultrastructural and biochemical basis for hepatitis C virus morphogenesis. Virus Genes 2017;53:151-64. [PMID: 28233195 DOI: 10.1007/s11262-017-1426-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
6 Rivett L, Alexander G. Is the conquest of Hepatitis C imminent? Expert Rev Mol Med 2019;21:e3. [PMID: 30909984 DOI: 10.1017/erm.2019.3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 King B, Tarr AW. How have retrovirus pseudotypes contributed to our understanding of viral entry? Future Virology 2017;12:569-81. [DOI: 10.2217/fvl-2017-0062] [Reference Citation Analysis]
8 Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines 2016;15:1535-44. [PMID: 27267297 DOI: 10.1080/14760584.2016.1194759] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
9 Mosa AI. Antigenic Variability. Front Immunol 2020;11:2057. [PMID: 33013870 DOI: 10.3389/fimmu.2020.02057] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Das S, Mullick R, Kumar A, Tandon H, Bose M, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Srinivasan N, Das S, Melkote Subbarao S, Karande AA. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies. J Gen Virol 2017;98:962-76. [PMID: 28221101 DOI: 10.1099/jgv.0.000735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Antiviral Res 2017;139:129-37. [PMID: 28062191 DOI: 10.1016/j.antiviral.2017.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Bamba M, Bordage S, Sahuc M, Moureu S, Samaillie J, Roumy V, Vauchel P, Dimitrov K, Rouillé Y, Dubuisson J, Tra Bi FH, Séron K, Sahpaz S. Anti-HCV Tannins From Plants Traditionally Used in West Africa and Extracted With Green Solvents. Front Pharmacol 2022;12:789688. [DOI: 10.3389/fphar.2021.789688] [Reference Citation Analysis]
13 Naik AS, Owsianka A, Palmer BA, O'Halloran CJ, Walsh N, Crosbie O, Kenny-Walsh E, Patel AH, Fanning LJ. Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus. PLoS One 2017;12:e0175349. [PMID: 28558001 DOI: 10.1371/journal.pone.0175349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Wei B, Kang J, Kibukawa M, Chen L, Qiu P, Lahser F, Marton M, Levitan D. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus. J Mol Diagn 2016;18:643-56. [PMID: 27393904 DOI: 10.1016/j.jmoldx.2016.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
15 Urbanowicz RA, Ball JK, Tarr AW. Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins. Methods Mol Biol 2019;1911:275-94. [PMID: 30593633 DOI: 10.1007/978-1-4939-8976-8_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Naik AS, Palmer BA, Crosbie O, Kenny-Walsh E, Fanning LJ. Humoral immune system targets clonotypic antibody-associated hepatitis C virus. J Gen Virol 2017;98:179-89. [PMID: 28284234 DOI: 10.1099/jgv.0.000659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Hraber P, Korber B, Wagh K, Giorgi EE, Bhattacharya T, Gnanakaran S, Lapedes AS, Learn GH, Kreider EF, Li Y, Shaw GM, Hahn BH, Montefiori DC, Alam SM, Bonsignori M, Moody MA, Liao HX, Gao F, Haynes BF. Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses 2015;7:5443-75. [PMID: 26506369 DOI: 10.3390/v7102881] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
18 Bagaglio S, Uberti-Foppa C, Morsica G. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs 2017;77:1043-55. [PMID: 28497432 DOI: 10.1007/s40265-017-0753-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
19 Guest JD, Pierce BG. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses 2021;13:837. [PMID: 34063143 DOI: 10.3390/v13050837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Pierce BG, Keck ZY, Foung SK. Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol 2016;20:55-63. [PMID: 27657659 DOI: 10.1016/j.coviro.2016.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
21 Tarr AW, Backx M, Hamed MR, Urbanowicz RA, McClure CP, Brown RJP, Ball JK. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. Antiviral Res 2018;160:25-37. [PMID: 30217650 DOI: 10.1016/j.antiviral.2018.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Balasco N, Barone D, Iaccarino E, Sandomenico A, De Simone A, Ruvo M, Vitagliano L. Intrinsic structural versatility of the highly conserved 412-423 epitope of the Hepatitis C Virus E2 protein. Int J Biol Macromol 2018;116:620-32. [PMID: 29758309 DOI: 10.1016/j.ijbiomac.2018.05.055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Sahuc ME, Sahli R, Rivière C, Pène V, Lavie M, Vandeputte A, Brodin P, Rosenberg AR, Dubuisson J, Ksouri R, Rouillé Y, Sahpaz S, Séron K. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J Virol 2019;93:e02009-18. [PMID: 30842319 DOI: 10.1128/JVI.02009-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 Cowton VM, Owsianka AM, Fadda V, Ortega-Prieto AM, Cole SJ, Potter JA, Skelton JK, Jeffrey N, Di Lorenzo C, Dorner M, Taylor GL, Patel AH. Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. NPJ Vaccines 2021;6:7. [PMID: 33420102 DOI: 10.1038/s41541-020-00269-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Khera T, Behrendt P, Bankwitz D, Brown RJP, Todt D, Doepke M, Khan AG, Schulze K, Law J, Logan M, Hockman D, Wong JAJ, Dold L, Gonzalez-Motos V, Spengler U, Viejo-Borbolla A, Ströh LJ, Krey T, Tarr AW, Steinmann E, Manns MP, Klein F, Guzman CA, Marcotrigiano J, Houghton M, Pietschmann T. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. J Hepatol 2019;70:593-602. [PMID: 30439392 DOI: 10.1016/j.jhep.2018.11.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
26 Pfaender S, Helfritz FA, Siddharta A, Todt D, Behrendt P, Heyden J, Riebesehl N, Willmann W, Steinmann J, Münch J, Ciesek S, Steinmann E. Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. Front Microbiol 2018;9:504. [PMID: 29636728 DOI: 10.3389/fmicb.2018.00504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Urbanowicz RA, McClure CP, King B, Mason CP, Ball JK, Tarr AW. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. J Gen Virol 2016;97:2265-79. [PMID: 27384448 DOI: 10.1099/jgv.0.000537] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
28 Del Campo JA, Parra-Sánchez M, Figueruela B, García-Rey S, Quer J, Gregori J, Bernal S, Grande L, Palomares JC, Romero-Gómez M. Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience. Int J Infect Dis 2018;67:114-7. [PMID: 29253705 DOI: 10.1016/j.ijid.2017.12.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
29 Fuerst TR, Pierce BG, Keck ZY, Foung SKH. Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus. Front Microbiol 2017;8:2692. [PMID: 29379486 DOI: 10.3389/fmicb.2017.02692] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
30 Weller R, Hueging K, Brown RJP, Todt D, Joecks S, Vondran FWR, Pietschmann T. Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. J Virol. 2017;91. [PMID: 28659481 DOI: 10.1128/jvi.00422-17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
31 Li Y, Wang R, Du X, Zhang M, Xie M. Genome-wide analysis for identification of adaptive diversification between hepatitis C virus subtypes 1a and 1b. Can J Microbiol 2016;62:608-16. [PMID: 27277863 DOI: 10.1139/cjm-2016-0156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Naik AS, Palmer BA, Crosbie O, Kenny-Walsh E, Fanning LJ. A single amino acid change in the hypervariable region 1 of hepatitis C virus genotype 4a aids humoral immune escape. J Gen Virol 2016;97:1345-9. [PMID: 26945008 DOI: 10.1099/jgv.0.000447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Prentoe J, Velázquez-Moctezuma R, Foung SK, Law M, Bukh J. Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. Hepatology 2016;64:1881-92. [PMID: 27351277 DOI: 10.1002/hep.28705] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
34 Meuleman TJ, Dunlop JI, Owsianka AM, van de Langemheen H, Patel AH, Liskamp RMJ. Immobilization by Surface Conjugation of Cyclic Peptides for Effective Mimicry of the HCV-Envelope E2 Protein as a Strategy toward Synthetic Vaccines. Bioconjug Chem 2018;29:1091-101. [PMID: 29382188 DOI: 10.1021/acs.bioconjchem.7b00755] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]